title: Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.
abstract: The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.
authors.affiliation: Pharmacy Department, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: M Kelli
authors.initials: MK
authors.lastname: Jordan
authors.forename: Aaron H
authors.initials: AH
authors.lastname: Burstein
authors.forename: Diane
authors.initials: D
authors.lastname: Rock-Kress
authors.forename: Raul M
authors.initials: RM
authors.lastname: Alfaro
authors.forename: Alice K
authors.initials: AK
authors.lastname: Pau
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Kovacs
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Piscitelli
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D018592:Cross-Over Studies; D015658:HIV Infections / Q000150:complications / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D008954:Models, Biological; D013411:Sulfadiazine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D014123:Toxoplasmosis / Q000188:drug therapy / Q000209:etiology
chemical_list: D000890:Anti-Infective Agents; D013411:Sulfadiazine